# A Phase IIa Proof-of-concept Study of NC-503 in Patients With Type II Diabetes

> **NCT00675857** · PHASE2 · COMPLETED · sponsor: **Bellus Health Inc. - a GSK company** · enrollment: 200 (estimated)

## Conditions studied

- Diabetes Mellitus, Type 2
- Metabolic Syndrome X

## Interventions

- **DRUG:** NC-503 (eprodisate disodium)
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT00675857
- **Lead sponsor:** Bellus Health Inc. - a GSK company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2010-01
- **Final completion:** 2010-05
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2010-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00675857

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00675857, "A Phase IIa Proof-of-concept Study of NC-503 in Patients With Type II Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00675857. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*